|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2200063049 |
|
最近更新日期: Date of Last Refreshed on: |
2022-08-29 15:38:24 |
|
注册时间: Date of Registration: |
2022-08-29 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
山莨菪碱在晚发型子痫前期患者围术期应用对胎儿血氧分压及apgar分的影响 |
|
Public title: |
Effect of anisodamine on fetal oxygen partial pressure and Apgar score in patients with late-onset preeclampsia during perioperative period |
|
注册题目简写: |
山莨菪碱在晚发型子痫前期患者围术期应用对胎儿血氧分压及apgar分的影响 |
|
English Acronym: |
Effect of anisodamine on fetal oxygen partial pressure and Apgar score in patients with late-onset preeclampsia during perioperative period |
|
研究课题的正式科学名称: |
山莨菪碱在LO-PE患者围术期应用对胎儿血氧分压及apgar评分的影响 |
|
Scientific title: |
Effect of anisodamine on fetal oxygen partial pressure and Apgar score in patients with LO-PE during perioperative period |
|
研究课题代号(代码): Study subject ID: |
无 |
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
无 |
|
申请注册联系人: |
徐颖 |
研究负责人: |
徐颖 |
|
Applicant: |
xuying |
Study leader: |
xuying |
|
申请注册联系人电话: Applicant telephone: |
15329329737 |
研究负责人电话:
Study leader's |
15329329737 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
337368230@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
337368230@qq.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
遵义医科大学 |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
|
|
申请注册联系人通讯地址: |
贵州省遵义市汇川区 |
研究负责人通讯地址: |
贵州省遵义市汇川区 |
|
Applicant address: |
Huichuan District, Zunyi City, Guizhou Province |
Study leader's address: |
Huichuan District, Zunyi City, Guizhou Province |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
遵义医科大学第三附属医院 |
||
|
Applicant's institution: |
The Third Affiliated Hospital of Zunyi Medical University |
||
|
研究负责人所在单位: |
|
||
|
Affiliation of the Leader: |
|
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2022-122 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
遵义医科大学第三附属医院伦理委员会 |
||
|
Name of the ethic committee: |
Ethics Committee of the Third Affiliated Hospital of Zunyi Medical University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2013-08-17 00:00:00 | ||
|
伦理委员会联系人: |
屠琳 |
||
|
Contact Name of the ethic committee: |
TuLin |
||
|
伦理委员会联系地址: |
贵州省遵义市汇川区凤凰北路98号 |
||
|
Contact Address of the ethic committee: |
98 Fenghuang North Road, Huichuan District, Zunyi City, Guizhou Province, China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
||
|
研究实施负责(组长)单位: |
遵义医科大学第三附属医院 |
||||||||||||||||||||||
|
Primary sponsor: |
The Third Affiliated Hospital of Zunyi Medical University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
遵义医科大学第三附属医院 |
||||||||||||||||||||||
|
Primary sponsor's address: |
The Third Affiliated Hospital of Zunyi Medical University |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
个人 |
||||||||||||||||||||||
|
Source(s) of funding: |
personal |
||||||||||||||||||||||
|
研究疾病: |
晚发型子痫前期 |
||||||||||||||||||||||
|
Target disease: |
Late-onset preeclampsia |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
探索性研究/预试验 | ||||||||||||||||||||||
|
Study phase: |
0 |
||||||||||||||||||||||
|
研究设计: |
单病例随机对照研究 |
||||||||||||||||||||||
|
Study design: |
N of 1 Trial |
||||||||||||||||||||||
|
研究目的: |
本研究拟通过观察新生儿血氧分压及apgar评分等指标变化,以评价山莨菪碱在晚发型子痫前期应用的有效意义,为临床诊疗中合并有晚发型子痫前期产妇的围术期麻醉前用药及管理提供参考。 |
||||||||||||||||||||||
|
Objectives of Study: |
The purpose of this study was to evaluate the effectiveness of anisodamine in late-onset preeclampsia by observing the changes of neonatal blood oxygen partial pressure and Apgar score, and to provide reference for perioperative preanesthetic medication and management of parturients with late-onset preeclampsia in clinical diagnosis and treatment. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
山莨菪碱主要是从茄科类植物——唐古特山莨菪根里提取出的一种生物碱,我国主要用它来治疗一些平滑肌痉挛、中毒性休克以及一些血管性的疾病,术前1小时静脉缓慢推注山莨菪碱10mg稀释到10ml。 |
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
Anisodamine is an alkaloid extracted from the root of the solanum family -- Tanggute anisodamine. It is mainly used in China to treat some smooth muscle spasm, toxic shock and some vascular diseases. Anisodamine 10mg diluted to 10ml was injected intravenously 1 hour before operation. |
||||||||||||||||||||||
|
纳入标准: |
(1)符合《妇产科学(第七版)》诊断标准首次确诊为妊娠期高血压疾病中晚发型子痫前期产妇 (2)ASAⅡ ~Ⅲ 级、单胎、无椎管内麻醉禁忌。 |
||||||||||||||||||||||
|
Inclusion criteria |
(1) According to the diagnostic criteria of Obstetrics and Gynecology (Seventh Edition), the first diagnosed pregnant women with hypertensive disorder complicating pregnancy and late-onset preeclampsia(2) ASA Ⅱ ~ Ⅲ (3)single pregnancy |
||||||||||||||||||||||
|
排除标准: |
(1)既往高血压病史 (2)胎儿宫内窘迫者 (3)合并其他妊娠期并发症者 (4)合并有严重的心、脑、肾等重要脏器器质性疾病 (5)有颅内压增高、青光眼、幽门梗阻等禁忌症 (6)凝血功能异常 |
||||||||||||||||||||||
|
Exclusion criteria: |
(1) History of hypertension (2) intrauterine fetal distress (3) complicated with other pregnancy complications (4) complicated with serious organic diseases of the heart, brain, kidney and other important organs (5) contraindations such as increased intracranial pressure, glaucoma, pyloric obstruction (6) abnormal coagulation function |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2022-08-15 00:00:00至 To 2023-03-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2022-08-15 00:00:00 至 To 2023-03-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
女性 |
Gender: |
Female |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
除研究者外的采用随机数字表发随机分为两组 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
All participants except the investigator were randomly divided into two groups using a random number table |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
双盲法 |
|
Blinding: |
double-blind |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
日期:2023年 5月-6月,通过ResMan平台网址:www.medresman.org |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
Date: May-June 2023, via ResMan platform at www.medresman.org |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
数据采集使用CRF表,管理使用ResMan平台 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
CRF table was used for data collection and ResMan platform was used for management |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |